Post by AGC Biologics

𝐅𝐥𝐞𝐱𝐢𝐛𝐢𝐥𝐢𝐭𝐲 𝐢𝐧 𝐛𝐢𝐨𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐢𝐬 𝐤𝐞𝐲 𝐭𝐨 𝐚𝐝𝐚𝐩𝐭𝐢𝐧𝐠 𝐭𝐨 𝐚𝐧 𝐞𝐯𝐞𝐫-𝐜𝐡𝐚𝐧𝐠𝐢𝐧𝐠 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐦𝐚𝐫𝐤𝐞𝐭. In this interview with BioSpace, AGC Biologics Principal Scientist, Anders Cai Holm Hansen, provides expert insights on why scale-out manufacturing may be the best strategy for: ✅Derisking demand uncertainty ✅Accelerating timelines ✅Reducing expenses Rethink scale-up - see how scaling out with parallel single-use bioreactors can support your changing needs. https://hubs.ly/Q04bCGLW0 #SingleUseTechnologies #ScaleOut #yourfriendlyCDMOexpert